Delving into the Latest Updates on SMU-L11 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

TLR7

Mechanism

TLR7 agonists(Toll like receptor 7 agonists)

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal Diseases

Active Indication

Melanoma

Inactive Indication-

Originator Organization

Southern Medical University

Active Organization

Southern Medical University

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Structure

Molecular FormulaC19H24N4O

InChIKeyYRCAPNRYNCJHGV-UHFFFAOYSA-N

CAS Registry-

Immunotherapy targeting the toll-like receptor 7 (TLR7) is a promising strategy for cancer treatment. Herein, we describe the design and synthesis of a series of imidazoquinoline-based TLR7 agonists and assess NF-κB pathway activation using HEK-Blue hTLR7 cells to identify the most potent small-molecule TLR7 agonist, SMU-L11 (EC₅₀ = 0.024 ± 0.002 μM). In vitro experiments demonstrated that SMU-L11 specifically activated TLR7, resulting in recruitment of the MyD88 adaptor protein and activation of the NF-κB and MAPK signaling pathways. Moreover, SMU-L11 was found to exert immune-enhancing effects by significantly inducing the secretion of proinflammatory cytokines in murine dendritic cells, macrophages, and human peripheral blood mononuclear cells while promoting M1 macrophage polarization. In vivo studies using a B16-F10 mouse tumor model showed that SMU-L11 significantly enhanced immune cell activation and augmented CD4⁺ T and CD8⁺ T-cell proliferation, directly killing tumor cells and inhibiting tumor growth.

100 Deals associated with SMU-L11

Login to view more data